A. Ari Hakimi, MD

Articles by A. Ari Hakimi, MD

One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.

Translating Rare Kidney Cancer Research into Clinical Trials

July 31st 2025

One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.

“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.

Pushing for Clinical Trials and Advocating for Patients in Rare Kidney Cancers

ByA. Ari Hakimi, MD

July 30th 2025

“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.

A. Ari Hakimi, MD

Articles by A. Ari Hakimi, MD

Translating Rare Kidney Cancer Research into Clinical Trials

Pushing for Clinical Trials and Advocating for Patients in Rare Kidney Cancers

Latest Updated Articles

Trending on CancerNetwork

Novel SSTR-Targeted Alpha Therapy Shows “Encouraging” Activity in GEP-NETs

Pembrolizumab Combo Does Not Significantly Improve OS in Unresectable HCC

Radiotherapy Plus Chemoimmunotherapy Improves Frontline ES-SCLC Prognosis

Durvalumab Plus Concurrent CRT Does Not Add Benefit in Stage III NSCLC

HER3-DXd Yields Activity in NSCLC, Breast Cancer Brain Metastasis Groups